Press Releases

Date	Title and Summary	Additional Formats
Toggle Summary Mar 21, 2017	Evoke Pharma's Phase 3 Results for Gimoti Accepted as Late-Breaker for Presentation at Digestive Disease Week 2017 SOLANA BEACH, Calif., March 21, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the Company's abstract detailing compelling Phase 3 trial data for Gimoti™	View HTML Evoke Pharma's Phase 3 Results for Gimoti Accepted as Late-Breaker for Presentation at Digestive Disease Week 2017 15.8 KB
Toggle Summary Jun 29, 2021	Evoke Pharma, EVERSANA and The International Foundation for Gastrointestinal Disorders Announce Membership into IFFGD’s Industry Council Extends commitment toward supporting patients experiencing Diabetic Gastroparesis through focused collaborations and Sponsorship of the 30th Anniversary Digestive Health Virtual Walk SOLANA BEACH, Calif. , CHICAGO , and MOUNT PLEASANT, S.C. , June 29, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc.	View HTML PDF Version
Toggle Summary Oct 18, 2023	Evoke Pharma’s Abstract Entitled “Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients” to Be Presented at The American College of Gastroenterology (ACG) 2023 An Selected for a Distinguished Oral Plenary Presentation SOLANA BEACH, Calif. , Oct. 18, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide)	View HTML PDF Version
Toggle Summary Sep 29, 2021	Evoke Pharma’s Commercial Partner EVERSANA, Receives PM360’s Trailblazer Initiative Award for Innovation in Healthcare Marketing for GIMOTI Award for “Spray Away” Campaign seeking to drive patient and provider awareness for the novel nasal spray treatment of symptoms of Diabetic Gastroparesis SOLANA BEACH, Calif. , Sept. 29, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma® (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments	View HTML PDF Version
Toggle Summary Aug 16, 2018	Evoke Pharma’s Gimoti™ NDA Accepted for FDA Review April 1, 2019 PDUFA Target Goal Date Gimoti Brand Name Conditionally Accepted SOLANA BEACH, Calif. , Aug. 16, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the Company’s	View HTML PDF Version
Toggle Summary May 04, 2023	Evoke Pharma’s Real-World Healthcare Utilization Data Comparing GIMOTI® to Oral Metoclopramide to Be Presented at Digestive Disease Week (DDW) 2023 Compelling data elevated to distinguished DDW oral plenary session GIMOTI to be showcased in additional activities at conference SOLANA BEACH, Calif. , May 04, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma , Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for	View HTML PDF Version
Toggle Summary Jan 04, 2017	Evoke Provides Additional Data Demonstrating Statistically Significant Benefit for Gimoti in Moderate to Severe Patients in Phase 3 Diabetic Gastroparesis Trial Nausea and abdominal pain symptoms significantly reduced in patients with higher symptom severity	View HTML Evoke Provides Additional Data Demonstrating Statistically Significant Benefit for Gimoti in Moderate to Severe Patients in Phase 3 Diabetic Gastroparesis Trial 25.5 KB
Toggle Summary Sep 28, 2015	Evoke Reaches Study Enrollment Milestone Associated With Credit Facility 150 Patients Enrolled in Phase 3 Clinical Trial	View HTML Evoke Reaches Study Enrollment Milestone Associated With Credit Facility 15.7 KB
Toggle Summary Aug 18, 2015	Evoke Receives Favorable Response From U.S. Food and Drug Administration Regarding Pediatric Study Plan for EVK-001 SOLANA BEACH, Calif. , Aug. 18, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the receipt of a letter from the U.S. Food and Drug Administration (FDA) indicating the agency's	View HTML Evoke Receives Favorable Response From U.S. Food and Drug Administration Regarding Pediatric Study Plan for EVK-001 16.6 KB
Toggle Summary May 20, 2020	Evoke Receives FDA Conditional Acceptance of Gimoti Brand Name Following NDA Resubmission SOLANA BEACH, Calif. , May 20, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the U.S. Food and Drug Administration (FDA) has conditionally accepted the proprietary brand	View HTML PDF Version